Spinedi E, Docena G
Int J Mol Sci. 2024; 25(21).
PMID: 39519291
PMC: 11546880.
DOI: 10.3390/ijms252111741.
Topczewska P, Savvopoulou A, Cosovanu C, Klose C
Front Cell Dev Biol. 2024; 12:1420313.
PMID: 39149516
PMC: 11325031.
DOI: 10.3389/fcell.2024.1420313.
Deka A, Kumar N, Basu S, Chawla M, Bhattacharya N, Ali S
EMBO J. 2024; 43(18):3895-3915.
PMID: 39060515
PMC: 11405688.
DOI: 10.1038/s44318-024-00182-6.
Bachanova P, How J, Dzeng R, Mukherjee S, Pavlovic M, Lombardi J
EJHaem. 2024; 5(3):573-577.
PMID: 38895092
PMC: 11182394.
DOI: 10.1002/jha2.868.
Barron A, Fabre T, De S
F1000Res. 2024; 13:54.
PMID: 38681509
PMC: 11053351.
DOI: 10.12688/f1000research.143472.1.
Advances in the study of tertiary lymphoid structures in the immunotherapy of breast cancer.
Li X, Xu H, Du Z, Cao Q, Liu X
Front Oncol. 2024; 14:1382701.
PMID: 38628669
PMC: 11018917.
DOI: 10.3389/fonc.2024.1382701.
Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application.
Zhang Y, Xu M, Ren Y, Ba Y, Liu S, Zuo A
Mol Cancer. 2024; 23(1):75.
PMID: 38582847
PMC: 10998345.
DOI: 10.1186/s12943-024-01980-6.
Tertiary lymphoid structures in cancer: immune mechanisms and clinical implications.
Wang S, Wang H, Li C, Liu B, He S, Tu C
MedComm (2020). 2024; 5(3):e489.
PMID: 38469550
PMC: 10925885.
DOI: 10.1002/mco2.489.
B cell development and antibody responses in human immune system mice: current status and future perspective.
Zhang T, Liu W, Yang Y
Sci China Life Sci. 2024; 67(4):645-652.
PMID: 38270770
DOI: 10.1007/s11427-023-2462-8.
Heterogeneity of tertiary lymphoid structures in cancer.
You X, Koop K, Weigert A
Front Immunol. 2023; 14:1286850.
PMID: 38111571
PMC: 10725932.
DOI: 10.3389/fimmu.2023.1286850.
Dynamics and specificities of T cells in cancer immunotherapy.
Oliveira G, Wu C
Nat Rev Cancer. 2023; 23(5):295-316.
PMID: 37046001
PMC: 10773171.
DOI: 10.1038/s41568-023-00560-y.
Immune subset-committed proliferating cells populate the human foetal intestine throughout the second trimester of gestation.
Guo N, Li N, Jia L, Jiang Q, Schreurs M, van Unen V
Nat Commun. 2023; 14(1):1318.
PMID: 36899020
PMC: 10006174.
DOI: 10.1038/s41467-023-37052-4.
Aldh1a2 + fibroblastic reticular cells regulate lymphocyte recruitment in omental milky spots.
Yoshihara T, Okabe Y
J Exp Med. 2023; 220(5).
PMID: 36880532
PMC: 9997506.
DOI: 10.1084/jem.20221813.
Tertiary Lymphoid Structures Are Associated with a Favorable Prognosis in High-Grade Serous Ovarian Cancer Patients.
Zhang K, Xie X, Zou L, Guo S
Reprod Sci. 2023; 30(8):2468-2480.
PMID: 36759495
DOI: 10.1007/s43032-023-01188-x.
Embryonic ILC-poiesis across tissues.
Hernandez-Torres D, Stehle C
Front Immunol. 2023; 13:1040624.
PMID: 36605193
PMC: 9807749.
DOI: 10.3389/fimmu.2022.1040624.
The Impact of Stem/Progenitor Cells on Lymphangiogenesis in Vascular Disease.
Mou R, Chen K, Zhu P, Xu Q, Ma L
Cells. 2022; 11(24).
PMID: 36552820
PMC: 9776475.
DOI: 10.3390/cells11244056.
The Role of Interleukin-7 in the Formation of Tertiary Lymphoid Structures and Their Prognostic Value in Gastrointestinal Cancers.
Ware M, Wolfarth A, Goon J, Ezeanya U, Dhar S, Ferrando-Martinez S
J Immunother Precis Oncol. 2022; 5(4):105-117.
PMID: 36483588
PMC: 9714415.
DOI: 10.36401/JIPO-22-10.
Tertiary lymphoid structures as unique constructions associated with the organization, education, and function of tumor-infiltrating immunocytes.
Chen J, Chen J, Wang L
J Zhejiang Univ Sci B. 2022; 23(10):812-822.
PMID: 36226536
PMC: 9561406.
DOI: 10.1631/jzus.B2200174.
The CXCL13/CXCR5 Immune Axis in Health and Disease-Implications for Intrathecal B Cell Activities in Neuroinflammation.
Harrer C, Otto F, Radlberger R, Moser T, Pilz G, Wipfler P
Cells. 2022; 11(17).
PMID: 36078057
PMC: 9454489.
DOI: 10.3390/cells11172649.
Regulative role of the CXCL13-CXCR5 axis in the tumor microenvironment.
Tan P, Shi M, Lai L, Tang Z, Xie N, Xu H
Precis Clin Med. 2022; 1(1):49-56.
PMID: 35694127
PMC: 8982482.
DOI: 10.1093/pcmedi/pby006.